Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics (NQ: FATE )

58.16 USD -0.84 (-1.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,391,819
Open 58.91
Bid (Size) 58.00 (5)
Ask (Size) 59.15 (1)
Prev. Close 59.00
Today's Range 57.17 - 59.77
52wk Range 42.64 - 121.16
Shares Outstanding 95,184,547
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
Peer-Reviewed Cell Stem Cell Publication Highlights Shared Metabolic, Transcriptional, and Functional Features of FT538 and Adaptive NK Cells 
From GlobeNewswire News Releases
Tentarix Biotherapeutics Emerges with $50 Million Series A
Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital. 
From Business Wire News Releases

Performance

YTD
-35.15%
-35.15%
1 Month
-10.32%
-10.32%
3 Month
-29.94%
-29.94%
6 Month
-36.79%
-36.79%
1 Year
+24.01%
+24.01%

More News

Read More
Fate Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
3 Biotech Stocks to Watch Now
Tags Benzinga FATE Market News
From Benzinga
How The Parts Add Up: FNY Targets $86
Tags ETFs
From ETF Channel
First Week of May 2022 Options Trading For Fate Therapeutics
Tags Stocks
From Market News Video
Nina Deka: Healthcare Technology Still In Early Stages Of Disruption
From Investor's Business Daily
Peek Under The Hood: FNX Has 12% Upside
Tags ETFs
From ETF Channel
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
Tags FATE Market News ARKK
From Motley Fool
Fate Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
From Investor's Business Daily
Fate Therapeutics Sees Relative Strength Rating Climb To 78
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.